JP6670751B2 - ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その塩及びその使用方法 - Google Patents

７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その塩及びその使用方法 Download PDF

Info

Publication number
JP6670751B2
JP6670751B2 JP2016554306A JP2016554306A JP6670751B2 JP 6670751 B2 JP6670751 B2 JP 6670751B2 JP 2016554306 A JP2016554306 A JP 2016554306A JP 2016554306 A JP2016554306 A JP 2016554306A JP 6670751 B2 JP6670751 B2 JP 6670751B2
Authority
JP
Japan
Prior art keywords
compound
cancer
treatment
subject
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016554306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503850A (ja
JP2017503850A5 (enExample
Inventor
ストグニュー、マーティン
アレン、ジョシュア・イー
ポットーフ、リチャード・エス
ラオ ナラガンチュー、バースカラ
ラオ ナラガンチュー、バースカラ
オルソン、ゲイリー・エル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoceutics Inc
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53057842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6670751(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/208,657 external-priority patent/US9265765B2/en
Priority claimed from US14/341,392 external-priority patent/US9376437B2/en
Priority claimed from PCT/US2014/048241 external-priority patent/WO2015073072A1/en
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Publication of JP2017503850A publication Critical patent/JP2017503850A/ja
Publication of JP2017503850A5 publication Critical patent/JP2017503850A5/ja
Application granted granted Critical
Publication of JP6670751B2 publication Critical patent/JP6670751B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
JP2016554306A 2013-11-15 2014-09-12 ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その塩及びその使用方法 Active JP6670751B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361904718P 2013-11-15 2013-11-15
US61/904,718 2013-11-15
US14/208,657 US9265765B2 (en) 2013-03-13 2014-03-13 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-A]pyrido[4,3-D]pyrimidin-5(3H)-one, salts thereof and methods of using the same in combination therapy
US14/208,657 2014-03-13
US14/341,392 2014-07-25
USPCT/US2014/048241 2014-07-25
US14/341,392 US9376437B2 (en) 2013-03-13 2014-07-25 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
PCT/US2014/048241 WO2015073072A1 (en) 2013-11-15 2014-07-25 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
PCT/US2014/055373 WO2015073109A1 (en) 2013-11-15 2014-09-12 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019233099A Division JP2020097577A (ja) 2013-11-15 2019-12-24 ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その塩及びその使用方法

Publications (3)

Publication Number Publication Date
JP2017503850A JP2017503850A (ja) 2017-02-02
JP2017503850A5 JP2017503850A5 (enExample) 2017-10-12
JP6670751B2 true JP6670751B2 (ja) 2020-03-25

Family

ID=53057842

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016554306A Active JP6670751B2 (ja) 2013-11-15 2014-09-12 ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その塩及びその使用方法
JP2019233099A Pending JP2020097577A (ja) 2013-11-15 2019-12-24 ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その塩及びその使用方法
JP2022076459A Pending JP2022105170A (ja) 2013-11-15 2022-05-06 ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法
JP2024027134A Active JP7870305B2 (ja) 2013-11-15 2024-02-27 ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法
JP2026020546A Pending JP2026086693A (ja) 2013-11-15 2026-02-11 ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019233099A Pending JP2020097577A (ja) 2013-11-15 2019-12-24 ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その塩及びその使用方法
JP2022076459A Pending JP2022105170A (ja) 2013-11-15 2022-05-06 ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法
JP2024027134A Active JP7870305B2 (ja) 2013-11-15 2024-02-27 ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法
JP2026020546A Pending JP2026086693A (ja) 2013-11-15 2026-02-11 ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その塩及びその使用方法

Country Status (25)

Country Link
EP (4) EP3546461B1 (enExample)
JP (5) JP6670751B2 (enExample)
KR (5) KR102742700B1 (enExample)
CN (2) CN106163524B (enExample)
AU (4) AU2014349150B2 (enExample)
BR (1) BR112016011072B1 (enExample)
CA (2) CA2930535C (enExample)
CY (2) CY1121628T1 (enExample)
DK (2) DK3546461T3 (enExample)
EA (1) EA033744B1 (enExample)
ES (2) ES2895600T3 (enExample)
HR (2) HRP20190814T1 (enExample)
HU (2) HUE043291T2 (enExample)
IL (6) IL296386B2 (enExample)
LT (2) LT3546461T (enExample)
ME (1) ME03387B (enExample)
MX (3) MX2016006318A (enExample)
PL (2) PL3068401T3 (enExample)
PT (2) PT3546461T (enExample)
RS (2) RS62572B1 (enExample)
SG (1) SG10201809189UA (enExample)
SI (2) SI3546461T1 (enExample)
SM (2) SMT201900291T1 (enExample)
TR (1) TR201906711T4 (enExample)
WO (1) WO2015073109A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021050209A (ja) * 2015-01-30 2021-04-01 オンコシューティクス インコーポレイテッドＯｎｃｏｃｅｕｔｉｃｓ，Ｉｎｃ． ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900291T1 (it) 2013-11-15 2019-07-11 Oncoceutics Inc 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidriomidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso
WO2017132661A2 (en) * 2016-01-29 2017-08-03 Oncoceutics, Inc. G protein-coupled receptor (gpcr) modulation by imipridones
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
US11091483B2 (en) * 2016-08-12 2021-08-17 Madera Therapeutics, LLC Protein kinase regulators
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
JP2022500408A (ja) * 2018-09-12 2022-01-04 デノボ バイオファーマ エルエルシー エンザスタウリンとｂｔｋの阻害剤との組合せおよびその使用
US12636293B2 (en) 2019-04-04 2026-05-26 Cmtx Biotech Inc. Methods of treating charcot-marie-tooth disease
KR102536315B1 (ko) 2020-09-11 2023-05-25 아주대학교산학협력단 네라티닙을 유효성분으로 포함하는 퇴행성 관절염 예방 또는 치료용 조성물
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途
EP4684834A1 (de) 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
NZ535349A (en) * 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US20080221135A1 (en) * 2005-05-13 2008-09-11 Bristol-Myers Squibb Company Combination therapy
AU2009324464B2 (en) * 2008-12-11 2016-05-05 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US9724337B2 (en) * 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
CA2795952A1 (en) 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
JP5863058B2 (ja) * 2010-05-17 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １Ｈ−イミダゾ［４，５−ｃ］キノリン
US8735386B2 (en) * 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
WO2012138789A2 (en) * 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
RS67757B1 (sr) * 2011-04-29 2026-03-31 Penn State Res Found Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
PL2968294T3 (pl) 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
SMT201900291T1 (it) 2013-11-15 2019-07-11 Oncoceutics Inc 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidriomidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, suoi sali e metodi d'uso
HUE069651T2 (hu) * 2014-03-31 2025-03-28 Scripps Research Inst Farmakofór TRAIL indukcióra

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021050209A (ja) * 2015-01-30 2021-04-01 オンコシューティクス インコーポレイテッドＯｎｃｏｃｅｕｔｉｃｓ，Ｉｎｃ． ７−ベンジル−４−（２−メチルベンジル）−２，４，６，７，８，９−ヘキサヒドロイミダゾ［１，２−ａ］ピリド［３，４−ｅ］ピリミジン−５（１ｈ）−オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法
JP7579684B2 (ja) 2015-01-30 2024-11-08 オンコシューティクス インコーポレイテッド ７－ベンジル－４－（２－メチルベンジル）－２，４，６，７，８，９－ヘキサヒドロイミダゾ［１，２－ａ］ピリド［３，４－ｅ］ピリミジン－５（１ｈ）－オン、その類似体、およびこれらの塩ならびに治療におけるこれらの使用方法

Also Published As

Publication number Publication date
AU2020200875B2 (en) 2022-02-10
KR20240006008A (ko) 2024-01-12
CY1124832T1 (el) 2022-11-25
KR102318238B1 (ko) 2021-10-26
MX2016006318A (es) 2017-01-19
ES2895600T3 (es) 2022-02-22
IL288674A (en) 2022-02-01
AU2022203043B2 (en) 2024-09-12
EP3939594B1 (en) 2026-08-12
IL245603A0 (en) 2016-06-30
EP3546461B1 (en) 2021-08-11
SMT201900291T1 (it) 2019-07-11
IL268248B (en) 2021-03-25
JP2026086693A (ja) 2026-05-26
EP3068401B1 (en) 2019-02-27
JP2020097577A (ja) 2020-06-25
AU2014349150B2 (en) 2019-11-07
KR20220140042A (ko) 2022-10-17
IL268248A (en) 2019-09-26
EA033744B1 (ru) 2019-11-21
MX2022001966A (es) 2022-06-02
IL288674B2 (en) 2023-02-01
SG10201809189UA (en) 2018-11-29
BR112016011072A8 (pt) 2018-01-30
CA2930535C (en) 2023-08-29
RS58745B1 (sr) 2019-06-28
RS62572B1 (sr) 2021-12-31
JP7870305B2 (ja) 2026-06-04
ME03387B (me) 2020-01-20
JP2017503850A (ja) 2017-02-02
LT3546461T (lt) 2021-09-27
NZ721055A (en) 2021-09-24
PL3068401T3 (pl) 2019-08-30
TR201906711T4 (tr) 2019-05-21
HRP20211653T1 (hr) 2022-02-04
HUE056389T2 (hu) 2022-02-28
AU2020200875A1 (en) 2020-02-27
CN110669047A (zh) 2020-01-10
CA2930535A1 (en) 2015-05-21
CY1121628T1 (el) 2020-07-31
JP2022105170A (ja) 2022-07-12
HRP20190814T1 (hr) 2019-06-28
IL311202A (en) 2024-05-01
IL296386B2 (en) 2024-08-01
PT3546461T (pt) 2021-10-18
LT3068401T (lt) 2019-05-27
PL3546461T3 (pl) 2022-01-03
IL288674B (en) 2022-10-01
IL281785A (en) 2021-05-31
MX2020002814A (es) 2022-02-15
IL296386A (en) 2022-11-01
WO2015073109A1 (en) 2015-05-21
IL281785B (en) 2022-01-01
KR20250006309A (ko) 2025-01-10
CN106163524A (zh) 2016-11-23
BR112016011072B1 (pt) 2022-06-21
EP3068401A1 (en) 2016-09-21
EP3939594A1 (en) 2022-01-19
KR102742700B1 (ko) 2024-12-13
SI3068401T1 (sl) 2019-06-28
DK3546461T3 (da) 2021-09-13
KR20210129280A (ko) 2021-10-27
EP4792889A2 (en) 2026-08-19
ES2724331T3 (es) 2019-09-10
AU2024278350A1 (en) 2025-01-09
EP3068401A4 (en) 2017-08-16
CN106163524B (zh) 2019-11-08
IL245603B (en) 2019-07-31
HRP20211653T8 (hr) 2022-03-04
CA3204925A1 (en) 2015-05-21
IL296386B1 (en) 2024-04-01
SI3546461T1 (sl) 2021-11-30
AU2022203043A1 (en) 2022-05-26
PT3068401T (pt) 2019-06-04
EP3546461A1 (en) 2019-10-02
SMT202100607T1 (it) 2021-11-12
HUE043291T2 (hu) 2019-08-28
AU2014349150A1 (en) 2016-06-30
MX390132B (es) 2025-03-20
KR102453679B1 (ko) 2022-10-11
JP2024059840A (ja) 2024-05-01
DK3068401T3 (da) 2019-06-03
KR20160084469A (ko) 2016-07-13
EA201691008A1 (ru) 2016-10-31

Similar Documents

Publication Publication Date Title
US20240216379A1 (en) 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidaz0[1,2-a]pyrid0[3,4-e] pyrimidin-5 (1 h)-one, salts thereof and methods of using the same in combination therapy
AU2022203043B2 (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use
JP6446025B2 (ja) 癌に対する薬剤併用療法のための化合物
US10045992B2 (en) 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5 (1h)-one, salts thereof and methods of using the same in combination therapy
US20250241920A1 (en) 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e] pyrimidin-5 (1 h)-one, salts thereof and methods of using the same in combination therapy
HK40059802A (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof for use in the treatment of cancer
HK1227764A1 (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use
HK1227764B (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use
NZ721055B2 (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190827

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191224

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200302

R150 Certificate of patent or registration of utility model

Ref document number: 6670751

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250